



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 12.11.2021

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

**Subject: Submission of Standalone Unaudited Financial Results in compliance
With Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Unaudited Financial Results of the Company for the Quarter ended on 30th September, 2021.
- 2) Limited Review Report on Standalone Unaudited Financial Results for the quarter ended on 30th September, 2021.

Kindly take the aforesaid information on your record and oblige.

Thanking you,

Yours truly,
For **Norris Medicines Limited**



(Vinay Rana)
Company Secretary

Encl: As above



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
 Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
 Telephone : (02646) 223462, 227530
 Fax : (02646) 250126
 E-mail : contact@norrispharma.com
 Website : www.norrispharma.com
 CIN : L24230GJ1990PLC086581

Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2021

Sr. No.	Particulars	(Rs. in Lakhs)					
		Quarter Ended			Six Months Ended		Year Ended
		30.09.2021 Unaudited	30.06.2021 Unaudited	30.09.2020 Unaudited	30.09.2021 Unaudited	30.09.2020 Unaudited	31.03.2021 Audited
i	Revenue from Operations	219.91	489.33	316.49	709.24	500.72	1225.12
ii	Other Income	0	1.64	0.04	1.65	2.49	4.95
iii	Total Revenue (i+ii)	219.91	490.97	316.53	710.89	503.21	1230.07
iv	Expenses						
	(a) Cost of Materials Consumed	129.86	109.86	281.74	239.72	285.72	952.68
	(b) Changes in Inventories of Finished Goods, work in Progress and stock in trade	-6.47	209.93	-21.06	203.46	68.59	-78.60
	(c) Employee Benefit Expenses	68.71	61.05	80.51	129.76	129.01	310.04
	(d) Finance Costs	49.85	42.47	27.74	92.32	38.85	163.45
	(e) Depreciation and Amortisation Expense	16.15	16.15	18.00	32.31	36.00	66.70
	(f) Other expenditure	40.66	57.00	58.88	97.66	99.59	215.13
	Total Expenses (iv)	298.76	496.46	445.81	795.23	657.76	1629.40
v	Profit/ (Loss) before exceptional and extraordinary items and tax (iii-iv)	-78.85	-5.49	-129.28	-84.34	-154.55	-399.33
vi	Exceptional items	0	0	0	0	0	0
vii	Profit/ (Loss) before extraordinary items and tax (v-vi)	-78.85	-5.49	-129.28	-84.34	-154.55	-399.33
viii	Extraordinary items	0	0	0	0	0	0
ix	Profit/ (Loss) before Tax (vii-viii)	-78.85	-5.49	-129.28	-84.34	-154.55	-399.33
x	Tax Expense						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	96.86
xi	Profit / Loss after Tax	-78.85	-5.49	-129.28	-84.34	-154.55	-496.19
xii	Other Comprehensive Income	0	0	0	0	0	0
	Total Comprehensive Income for the period	-78.85	-5.49	-129.28	-84.34	-154.55	-496.19
xiii	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
xiv	- Basic and diluted	-0.79	-0.05	-1.29	-0.84	-1.55	-4.96

Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12.11.2021. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 30.9.2021.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited

Vimal D Shah
 Managing Director

Date: 12.11.2021
 Place: Chennai





NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Statement of Assets & Liabilities

(Rs. in Lakhs)

	As At 30.09.2021 Un audited	As At 31.03.2021 (Audited)
A . ASSETS		
1. Non Current Assets		
a) Property, Plant & Equipment	668.32	767.09
b) Capital Work in Progress		
c) Investment Property		
d) Financial Assets		
i) Investments	0.94	0.89
ii) Loans	0.95	0.59
iii) Others	39.19	37.44
e) Non Current Tax Assets (Net)	268.75	268.75
f) Other Non Current Assets	81.16	80.61
TOTAL NON CURRENT ASSETS	1059.31	1155.37
2. Current Assets		
a) Inventories	267.96	510.24
b) Financial Assets		
i) Trade Receivables	156.68	178.84
ii) Cash and Cash Equivalents	2.04	2.07
iii) Bank Balance other than "b" above.		
iv) Loans		
v) Others	81.75	132.16
TOTAL CURRENT ASSETS	508.42	823.31
TOTAL ASSETS	1567.73	1978.68
B. EQUITY & LIABILITIES		
1) Equity		
a) Equity Share Capital	992.58	992.58
b) Other Equity	-1891.94	-1735.61
Total Equity	-899.36	-743.03
2) Non Current Liabilities		
a) Financial Liabilities - Borrowings	1723.93	1552.31
b) Provisions		
c) Deferred Tax Liabilities (Net)		
d) Non Current Tax Liabilities (Net)		
Total Non - Current Liabilities	1723.93	1552.31
3) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	285.35	286.23
ii) Trade payables	217.85	524.15
iii) Other financial liabilities ,	59.34	244.20
b) Other Current Liabilities	0.00	0.00
c) Provisions	180.62	114.82
Total Current Liabilities	743.16	1169.4
TOTAL EQUITY AND LIABILITIES	1567.73	1978.68





NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
 Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
 Telephone : (02646) 223462, 227530
 Fax : (02646) 250126
 E-mail : contact@norrispharma.com
 Website : www.norrispharma.com
 CIN : L24230GJ1990PLC086581

Cash flow statement for the half year ended 30th September, 2021		(Rs. in Lakhs)	
		Half Year ended 30.09.2021	For Year Ended 31.03.2021
		Unaudited	Audited
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit/Loss before tax and extraordinary items	-84,33,218	-4,96,19,467
	Adjustments for :		
	Depreciation & Amortisation	0	66,69,892
	Deferred Tax Liability	32,30,765	96,85,855
	Interest Income	0	-1,30,239
	Interest Paid	0	1,63,44,830
	Profit/Loss on Investment in bonds	92,32,309	0
	Profit/Loss on sale of Fixed Assets	0	0
	Other Non Operating Income	0	0
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	40,29,856	-1,70,49,130
	Adjustments for Changes in Working Capital		
	Increase/Decrease in Trade Debtors	22,11,595	97,22,130
	Increase/Decrease in Inventories	2,42,28,536	-1,09,67,563
	Increase/Decrease in Loans & Advances, Trade Payables and Other Liabilities	50,40,799	-70,95,060
		-4,26,23,918	3,65,25,276
	Net cash from operations before taxation	-1,11,42,988	2,81,84,781
	Tax Paid	0	0
	CASH FLOW BEFORE EXTRA ORDINARY ITEM	-1,11,42,988	2,81,84,781
	Extra Ordinary Item	0	0
	NET CASH FROM OPERATING ACTIVITIES	-71,13,133	1,11,35,651
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	-5,53,884	-8,79,870
	Sale of Fixed Assets	0	0
	Investments Made during the year	0	0
	Long Term Advances	-2,66,822	1,30,918
	Receipt from Investment	0	0
	Interest Income	0	1,30,239
	Dividend Received	0	0
	Profit/Loss on sale of bonds	0	0
	Net Cash used in Investing Activities (B)	-8,20,706	-6,18,713
(C)	CASH FLOW FROM FINANCING ACTIVITIES:-		
	Share Capital	0	0
	Borrowings	1,71,62,591	54,00,050
	Interest paid	-92,32,309	-1,63,44,830
	Net Cash Used in Financing Activities (C)	79,30,282	-1,09,44,780
	Net Increase/Decrease in Cash and Cash Equivalents (A+B+C)	-3,556	-4,27,842
	Cash and Cash equivalents - Opening balance	2,07,134	6,34,975
	Cash and cash equivalents - Closing balance	2,03,577	2,07,134
		3,557	4,27,841
	Component of Cash & Cash Equivalents:		
	Cash on hand	1,09,236	75,011
	With Banks in Current Accounts	94,341	1,32,123
		2,03,577	2,07,134





C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

Limited Review Report

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

We have reviewed the accompanying statement of Standalone unaudited financial results ("the statement) of **NORRIS MEDICINES LIMITED** ("the company") for the quarter ended on **30th September, 2021** and for the year to date period from 1st April, 2021 to 30th September, 2021 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 date March 29, 2019. This Statement is the responsibility of the Company's Management and has been approved by the Board of directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of Companies Act 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.






C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards , i.e. Indian Accounting Standard (" Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 12/11/2021

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat

For, H. N. JADHAV & Co.
Chartered Accountants


CA HARISHCHANDRA JADAV
Proprietor
M. No. 040525
Firm Reg. No. 103801W
UDIN: 21040525AAAACY4645

